Week in Review: WuXi PharmaTech Pays $65 Million for Genomics Company

WuXi PharmaTech paid $65 million in cash to acquire NextCODE Health, a genomic analysis and bioinformatics company, that it hopes will become "an integrated global enterprise for applying genomics to medicine;" Fosun Pharma will invest $35 million in Amerigen Pharma, a US-China maker of hard-to-manufacture generic drugs; Hua Medicine closed a $25 million Series B financing that will underwrite a Phase II clinical trial of a GKA diabetes drug; Sihuan Pharma and partners will pay $67 million to privatize a Nanjing hospital; Shenzhen Hybio Pharma out-licensed US rights for a generic multiple sclerosis treatment to Akorn of the US; China Medical System Holdings of Shenzhen acquired China rights to two Novartis drugs; Phagelux of Shanghai in-licensed several biodegradable polymer delivery systems for its phage-based products; Fosun Pharma announced an $800 million budget for R&D during China's 13th Five-Year Plan (2016-2020); WuXi PharmaTech revealed a mobile app, WuXi V-Lab, to order chemical synthesis services; Ascentage Pharma of China received CFDA approval to begin clinical trials of a novel apoptosis cancer drug candidate; and Sirnaomics, a US-China biopharma, filed to begin China clinical trials of a short-interfering RNA (siRNA) drug. More details.... Stock Symbols: (NYSE: WX) (SHA: 600196; HK: 02196) (HK: 0460) (HK: 0867) (NYSE: NVS) (SHA: 600196; HK: 2196) Share this with colleagues: // //